Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.

  title={Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.},
  author={E Catherwood and William Fitzpatrick and Mark L. Greenberg and Peter T Holzberger and David J. Malenka and Barbara R. Gerling and John D. Birkmeyer},
  journal={Annals of internal medicine},
  volume={130 8},
The management of patients with nonvalvular atrial fibrillation requires that physicians assess the risks and benefits of two principal treatment options: antithrombotic therapy with control of the ventricular response or cardioversion to restore sinus rhythm. Because a series of large-scale, randomized trials demonstrated the efficacy of warfarin (1-6) or aspirin (5-8) in reducing the frequency of thromboembolic events, antithrombotic therapy plus rate control is considered the standard of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 19 extracted citations


Publications referenced by this paper.
Showing 1-10 of 97 references

Predicting treatment costs and life expectancy for end-stage renal disease.

The New England journal of medicine • 1978
View 6 Excerpts
Highly Influenced

Rates and predictors of embolic events following electrical cardioversion [Abstract

F Gentile, BK Khandheria, +3 authors J. Tajik
J Am Coll Cardiol. 1998;31(Suppl A):195A • 1998

Adverse effects of amiodarone at low dose: plus ça change.

Journal of the American College of Cardiology • 1997

Similar Papers

Loading similar papers…